# Bio-Techne (TECH) — Earnings

TECH · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/tech/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q3 2026 |
| Period end | Mar 31, 2026 |
| EPS actual | $0.53 |
| EPS estimate | $0.53 |
| EPS surprise | −0.79% |
| Revenue surprise | −1.48% |
| Revenue | $311.4M |
| Revenue estimate | $316.1M |
| Reported | May 6, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/842023/000110465926056302/tech-20260331x10q.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/a6f8fadc-5276-4119-1899-fff3c717cf8b.html) |

Bio-Techne reported fiscal Q3 2026 results on May 6, 2026. Earnings per share were $0.53, matching the $0.53 estimate on a rounded basis and 0.79% below it before rounding. Revenue was $311.4 million, 1.48% short of the $316.1 million consensus. Compared with Q3 2025, EPS fell about 5% from $0.56 and revenue slipped about 1.5% from $316.2 million.

The longer record is fairly flat. Annual EPS was $1.98 in fiscal 2022 and $2.00 in fiscal 2023, dipped to $1.78 in 2024 and recovered to $1.93 in 2025. The first three quarters of fiscal 2026 add up to $1.41, against $1.40 a year earlier. Quarterly EPS in the table ranged from $0.40 in Q2 2024 to $0.56 in Q3 2025. Revenue peaked at $317.0 million in Q4 2025. Over the 20 quarters shown, Bio-Techne beat the EPS estimate 12 times and missed 8 times.

The table does not yet include fiscal Q4 2026. Bio-Techne reported Q4 between August 4 and August 8 in each of the past five years, and Q1 between October 30 and November 5. The next figures will show whether the full fiscal year kept pace with the year-to-date total.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q3 2026 | May 6, 2026 | $0.53 | $0.53 | -0.79% | $316.1M | $311.4M |
| Q2 2026 | Feb 4, 2026 | $0.43 | $0.46 | 5.99% | $290.5M | $295.9M |
| Q1 2026 | Nov 5, 2025 | $0.42 | $0.42 | -0.33% | $291.3M | $286.6M |
| Q4 2025 | Aug 6, 2025 | $0.50 | $0.53 | 6.13% | $314.6M | $317.0M |
| Q3 2025 | May 7, 2025 | $0.51 | $0.56 | 10.32% | $317.2M | $316.2M |
| Q2 2025 | Feb 5, 2025 | $0.39 | $0.42 | 8.75% | $285.8M | $297.0M |
| Q1 2025 | Oct 30, 2024 | $0.38 | $0.42 | 10.06% | $280.2M | $289.5M |
| Q4 2024 | Aug 7, 2024 | $0.49 | $0.49 | -0.99% | $306.5M | $306.1M |
| Q3 2024 | May 1, 2024 | $0.45 | $0.48 | 6.01% | $292.2M | $303.4M |
| Q2 2024 | Feb 1, 2024 | $0.41 | $0.40 | -2.96% | $277.5M | $272.6M |
| Q1 2024 | Oct 31, 2023 | $0.43 | $0.41 | -5.68% | $287.7M | $276.9M |
| Q4 2023 | Aug 8, 2023 | $0.55 | $0.55 | 0.64% | $307.2M | $301.3M |
| Q3 2023 | May 3, 2023 | $0.53 | $0.53 | 0.38% | $296.6M | $294.1M |
| Q2 2023 | Feb 2, 2023 | $0.49 | $0.47 | -3.71% | $288.8M | $271.6M |
| Q1 2023 | Nov 1, 2022 | $0.46 | $0.45 | -2.75% | $281.8M | $269.7M |
| Q4 2022 | Aug 4, 2022 | $0.52 | $0.51 | -1.27% | $286.7M | $288.2M |
| Q3 2022 | May 4, 2022 | $0.50 | $0.54 | 7.15% | $279.3M | $290.4M |
| Q2 2022 | Feb 1, 2022 | $0.45 | $0.47 | 5.05% | $266.4M | $269.3M |
| Q1 2022 | Nov 2, 2021 | $0.43 | $0.46 | 6.27% | $252.8M | $257.7M |
| Q4 2021 | Aug 5, 2021 | $0.43 | $0.47 | 9.92% | $244.7M | $259.0M |

## Frequently Asked Questions

### When did Bio-Techne (TECH) last report earnings?

Bio-Techne last reported on May 6, 2026, covering fiscal Q3 2026.

### Did TECH beat earnings estimates?

No. Bio-Techne reported EPS of $0.53 for Q3 2026 against a $0.53 estimate — a 0.79% miss.

### How much revenue did TECH report last quarter?

Bio-Techne reported $311.4M in revenue for Q3 2026, against a consensus estimate of $316.1M.

## Similar Stocks

- [TMO](https://www.lighthorse.io/tickers/tmo) — Thermo Fisher Scientific Inc Common Stock
- [A](https://www.lighthorse.io/tickers/a) — Agilent Technologies, Inc. Common Stock
- [RVTY](https://www.lighthorse.io/tickers/rvty) — Revvity, Inc. Common Stock
- [MTD](https://www.lighthorse.io/tickers/mtd) — Mettler-Toledo International, Inc. Common Stock
- [IQV](https://www.lighthorse.io/tickers/iqv) — IQVIA Holdings, Inc. Common Stock
- [WAT](https://www.lighthorse.io/tickers/wat) — Waters Corporation Common Stock
- [CRL](https://www.lighthorse.io/tickers/crl) — Charles River Laboratories International, Inc. Common Stock
- [BIO](https://www.lighthorse.io/tickers/bio) — Bio-Rad Laboratories, Inc. Class A Common Stock
- [DHR](https://www.lighthorse.io/tickers/dhr) — Danaher Corporation Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).